Skip to content
10-Q/A

Quarterly Report

AXIM BIOTECHNOLOGIES, INC. AXIM

0001096906-24-001225

← back to feed
Filed
May 22, 2024 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 20, 2024 291.46M sh
Capex Q1 2024 · Mar 31, 2024 $2.84K
Operating Cash Flow restated Q1 2024 · Mar 31, 2024 −$252.51K
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$141.96K
Stockholders Equity Q1 2024 · Mar 31, 2024 −$7.45M
Stockholders Equity Q1 2024 · Dec 31, 2023 −$7.66M
Stockholders Equity Q1 2024 · Mar 31, 2023 −$6.16M
Stockholders Equity Q1 2024 · Dec 31, 2022 −$4.83M
Current Liabilities Q1 2024 · Mar 31, 2024 $4.8M
Current Liabilities Q1 2024 · Dec 31, 2023 $5.98M
Total Liabilities Q1 2024 · Mar 31, 2024 $11.38M
Total Liabilities Q1 2024 · Dec 31, 2023 $11.78M
Current Assets Q1 2024 · Mar 31, 2024 $96.71K
Current Assets Q1 2024 · Dec 31, 2023 $156.46K
Total Assets Q1 2024 · Mar 31, 2024 $3.93M
Total Assets Q1 2024 · Dec 31, 2023 $4.12M
Eps Diluted Q1 2024 · Mar 31, 2024 −$0.00
Eps Diluted restated Q1 2024 · Mar 31, 2023 −$0.01
Eps Basic Q1 2024 · Mar 31, 2024 −$0.00
Eps Basic restated Q1 2024 · Mar 31, 2023 −$0.01
Sga Expense restated Q1 2024 · Mar 31, 2024 $331.04K
Sga Expense Q1 2024 · Mar 31, 2023 $590.94K
Rd Expense Q1 2024 · Mar 31, 2024 $15.5K
Rd Expense Q1 2024 · Mar 31, 2023 $20.34K
Rd Expense Q1 2024 · Dec 31, 2021 $284.87K
Net Income Q1 2024 · Mar 31, 2024 −$292.3K
Net Income Q1 2024 · Mar 31, 2023 −$2.76M
Operating Income restated Q1 2024 · Mar 31, 2024 −$401.56K
Operating Income Q1 2024 · Mar 31, 2023 −$710.63K
Revenue Q1 2024 · Mar 31, 2024 $52.98K
Revenue Q1 2024 · Mar 31, 2023 $7.4K